Study Details

Back to Search Results

Erlotinib versus oral etoposide in patients with recurrent or refractory pediatric ependymoma

Terminated/Withdrawn
The study has stopped early and will not start again. Participants were not enrolled (for withdrawn studies), however if participants were enrolled, they are no longer being examined or treated.

Clinicaltrials.gov ID

The unique identification code given to each clinical study upon registration at ClinicalTrials.gov.
NCT01032070

Astellas Study ID

The unique identification code given by the study sponsor.

OSI-774-205

EudraCT ID

The unique identification code given to each clinical study upon registration at EudraCT (European Union Drug Regulating Authorities Clinical Trials Database).

2009-016836-11

Follow Trial

Condition

Ependymoma

Phase

These clinical trials are done to learn if an experimental treatment helps participants who have a specific condition or disease. Phase 2 trials usually include a larger group of participants than Phase 1 trials.

Phase 2

Age

1 years - 21 years

Sex

Female & Male

Product

N/A

Type

A type of clinical study in which participants are assigned to groups that receive one or more intervention/treatment (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.

Interventional

Trial Dates

Sep 2010 - Nov 2012

Masking

None (Open Label)

Enrollment number

25

A Randomized, Phase 2 Study of Single-agent Erlotinib versus Oral Etoposide in Patients with Recurrent or Refractory Pediatric Ependymoma

Study summary

Study documents

Study Documents, including study results, are available after a study is completed or terminated, according to Astellas Transparency policy.

Get More Information

Would you like more information about clinical trial sites that are recruiting participants for Erlotinib versus oral etoposide in patients with recurrent or refractory pediatric ependymoma? Contact us by filling our your information to the right and we’ll respond to you.

By clicking ["Continue/Submit"], you agree that Astellas may contact you by email with information to help you connect with clinical trial sites. While we can connect you to clinical trial sites, we cannot answer questions about any investigational therapy through email. Your consent to receiving emails is not a requirement to participate in a clinical trial or study. For more information, including how to unsubscribe at any time, see our Privacy Notice & Cookies Policy.

Locations

Steven D Hassenfeld Children’s Center – New York University

New York, United States, 10016

University of Wisconsin Pediatric Hematology/Oncology Department

Madison, United States, 53705-2275

Stanford University and Lucile Packard Children’s Hospital

Palo Alto, United States, 94304

Royal Manchester Children's Hospital Ward 84

Manchester, United Kingdom, M13 9W2

Birmingham Children's Hospital

Birmingham, United Kingdom, B4 6NH

Royal Marsden Hospital

Sutton, United Kingdom, SM2 5PT

Children's Medical Center, Dallas Center for Cancer and Blood Disorders

Dallas, United States, 75235

University of Alabama at Birmingham Dept. of Pediatric-Hematology/Oncology

Birmingham, United States, 35233

Children’s and Women’s Health Center of BC Division of Hematology/ Oncology/ BMT

Vancouver, Canada, V6H 3V4

University of Florida Shands Children's Hospital

Gainesville, United States, 32610-0296

Strollery Children's Hospital Division of Hematology/Oncology

Edmonton, Canada, T6G 2B7

Paediatric Oncology and Haematology Offices

Leeds, United Kingdom, LS1 3EX

Penn State Hershey Children's Hospital

Hershey, United States, 17110

Children's Memorial Medical Hospital

Chicago, United States, 60614

University of Miami

Miami, United States, 33136

Royal Hospital for Sick Children

Glasgow, United Kingdom, G3 8SJ

Oregon Health & Sciences University Doembecher Children's Hospital

Portland, United States, 97124

Center for Cancer and Blood Disorders-Phoenix Children's Hospital

Phoenix, United States, 85016

Hospital for Sick Children

Toronto, Canada, M5G 1X8

Alder Hey Children’s NHS Foundation Trust Department of Oncology

Liverpool, United Kingdom, L12 1AP

Amplatz Children's Hospital University of Minnesota Medical Center- Pediatric Hematology Oncology

Minneapolis, United States, 55455

University of Nottingham Children's Brain Tumour Research Centre

Nottingham, United Kingdom, NG7 2UH

Children's National Medical Center - D.C. Center for Cancer and Blood Disorders

Washington, United States, 20010

Emory University Children's Healthcare of Atlanta Aflac Cancer Center & Blood Disorders

Atlanta, United States, 30322

Children's Hospital of Orange County (CHOC)

Orange, United States, 92868

Columbia University Children's Hospital of New York Presbyterian Child & Adolescent Oncology Center

New York, United States, 10032

Children's Hospital of Pittsburgh of UPMC

Pittsburgh, United States, 15224

Dana-Farber Cancer Institute Department of Pediatric Neuro-oncology

Boston, United States, 02115

Johns Hopkins University School of Medicine

Baltimore, United States, 21287

Children's Hospital Center for Cancer and Blood Disorders

Aurora, United States, 80045

The purpose of this website is to offer education and information to patients and their families and friends, the public, and healthcare professionals about the clinical trial process. In addition, the website will provide specific information about Astellas clinical trials. Please read the complete Astellas Transparency Policy to learn about the clinical trial information available on this website

© ASTELLAS PHARMA GLOBAL DEVELOPMENT, INC.

POWERED BY:

Pharma Intelligence logo